Uncategorized
Ohr announces positive interim clinical results from Phase 2 wet AMD treatment study
Ohr Pharmaceuticals has announced that its phase 2 study of Squalamine eye drops for the treatment of wet age-related macular degeneration has produced positive top-line interim results, according to a company press release.“The data further validate not only the clinical utility of noninvasive topical eye drop therapies for macular and retinal disorders, but also the soundness of our company’s drug development science and our proprietary formulation technologies that enable topical dosing to achieve positive therapeutic effects in back-of-the-eye disorders,” Irach B. Taraporewala, Ohr president and CEO, said in the release.